Pyrimidyn-Based Dynamin Inhibitors as Novel Cytotoxic Agents

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Dynamin GTPase is essential for mitosis and cellular processes.
• Targeting dynamin offers a potential strategy for cancer therapy.
• Pyrimidine scaffolds are explored for their biological activities.

Purpose of the Study:

• To synthesize and evaluate pyrimidine-based compounds as dynamin GTPase inhibitors.
• To assess the correlation between dynamin inhibition and cytotoxicity in various cancer cell lines.
• To identify novel potent anticancer agents.

Main Methods:

• Synthesis of 69 pyrimidine-based compounds with varying substitution patterns.
• Assay of dynamin inhibition across different compound concentrations (1-60 μM).
• Cytotoxicity screening using a panel of 12 human and murine cancer cell lines.

Main Results:

• Di- and tri-substituted pyrimidines, particularly those with amino alkyl chains, showed highest dynamin inhibition.
• A strong positive correlation was observed between dynamin inhibition and broad-spectrum cytotoxicity.
• Two analogues, 31a and 31b, exhibited potent activity with average GI50 values of 1.0 and 0.78 μM, respectively.

Conclusions:

• Pyrimidine derivatives effectively inhibit dynamin GTPase.
• Dynamin inhibition is a viable strategy for developing broad-spectrum anticancer drugs.
• Compounds 31a and 31b represent promising leads for further anticancer drug development.